Chemo plus toripalimab for EBV-related stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether adding toripalimab (an immune therapy) to chemotherapy before surgery improves outcomes for people with EBV-related, locally advanced stomach or stomach-junction cancer. It aims to help the cancer respond better and reduce the chance of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form and agree to join voluntarily.
- You’re 18 to 80 years old, and you can walk around normally most days (ECOG 0–1).
- Your stomach or esophagus-stomach junction cancer was confirmed by biopsy, and it’s EBV-related based on a special test (ISH) on that biopsy.
- Your cancer stage fits “locally advanced” (cT2–4b, lymph nodes involved, and no distant spread—M0).
- Your blood counts and organ tests (liver, kidneys, blood clotting) are within safe ranges.
- You can provide biopsy and surgical tissue samples for additional lab testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.